Every Peptide

Peptide field guide

Glucagon-like peptide-1 (GLP-1)

An endogenous gut hormone peptide that signals through the GLP-1 receptor and forms the biological basis for GLP-1 receptor agonist drugs used in diabetes and obesity.

Evidence: strong Safety: moderate Status: clinical Updated: March 28, 2026 Metabolic healthDiabetesClinical

What it is

Glucagon-like peptide-1 (GLP-1) is an endogenous peptide hormone released from the gut after meals. In physiology, GLP-1 helps coordinate glucose control by increasing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and influencing appetite and food intake.

In medicine, GLP-1 is most relevant because it is the biological template for GLP-1 receptor agonists (GLP-1RAs), a class of peptide-based drugs used for type 2 diabetes and obesity (and studied for multiple cardiometabolic outcomes).

Why people care about it

The GLP-1 pathway sits at the center of modern metabolic therapeutics because GLP-1RAs can produce meaningful improvements in:

  • glycemic control in type 2 diabetes
  • body weight and appetite regulation
  • downstream cardiometabolic risk factors

GLP-1 itself is not typically used as a drug because it is rapidly degraded in the body. Many GLP-1RAs are engineered to last longer and achieve sustained receptor activation.

How it works (high level)

GLP-1 acts primarily via the GLP-1 receptor (GLP-1R). A key practical point is that GLP-1–mediated insulin secretion is glucose-dependent, which is part of why the pathway can have a different hypoglycemia risk profile than insulin or sulfonylureas.

Evidence landscape

  • For GLP-1RAs in type 2 diabetes and obesity: strong evidence, including large randomized trials for multiple products and outcomes.
  • For GLP-1RAs in type 1 diabetes: evidence is more mixed and historically focused on intermediate outcomes. Large randomized outcomes trials are limited.

Latest updates

  • 2026-03-28 (Depression signal meta-analysis, very high heterogeneity): A systematic review/meta-analysis (19 studies) reported higher odds of depression associated with GLP-1 receptor agonist use (OR 1.49; 95% CI 1.18 to 1.88), but between-study heterogeneity was extreme (I² 99.21%), limiting how literally the pooled estimate should be taken.

  • 2026-03-28 (SURPASS-CVOT post hoc cardiorenal composite: tirzepatide vs dulaglutide): In a post hoc analysis of the SURPASS-CVOT randomized trial in patients with type 2 diabetes and established CVD (13,165 participants), tirzepatide was associated with a lower incidence of a broad 6-component composite cardiovascular + kidney endpoint vs dulaglutide (HR 0.84; 95% CI 0.79 to 0.90).

  • 2026-03-27 (Tirzepatide safety meta-analysis in higher cardiovascular-risk trial populations): A systematic review/meta-analysis of 21 placebo-controlled randomized trials (8,043 participants) restricted to patients at increased risk of cardiovascular events found no evidence of a difference in serious adverse events vs placebo (OR 0.98; 95% CI 0.82 to 1.17; moderate certainty). All-cause mortality showed no evidence of a difference but was based on sparse data (very low certainty). Gastrointestinal non-serious adverse events (nausea, diarrhea, decreased appetite, vomiting) were more common with tirzepatide.

  • 2026-03-27 (TSH monitoring after GLP-1 RA initiation in older adults on levothyroxine): A Medicare target-trial emulation (2011–2020) comparing GLP-1 receptor agonist initiation vs SGLT-2 inhibitor initiation/ongoing use found similar TSH testing patterns within 1 year (about 83% tested; mean time ~130 days), despite GLP-1 therapies being more likely to drive weight loss that can change levothyroxine requirements.

  • 2026-03-25 (Heart failure spectrum, RCT meta-analysis preprint): A systematic review/meta-analysis of randomized evidence across heart failure phenotypes (14 studies; 18,558 patients) reported a non-significant primary composite of CV death + first HF hospitalization (HR 0.86; P=0.067). Symptom/function measures improved in HFpEF-with-obesity trials (KCCQ +7.4 points; 6MWD +17.6 m). The pooled all-cause mortality signal was driven largely by CVOT subgroup analyses, while dedicated HF trials were directionally harmful.

  • 2026-03-24 (Weight loss: GLP-1RAs vs bariatric surgery): A systematic review/meta-analysis pooled 15 studies (20,594 participants) comparing GLP-1 receptor agonists vs bariatric surgery for obesity outcomes. The pooled estimates favored bariatric surgery for larger, more sustained reductions in weight/BMI (especially beyond 1 year), with mixed findings at 6 months and substantial heterogeneity.

  • 2026-03-24 (Pancreatitis signal check, living RCT meta-analysis preprint): A living meta-analysis of 31 placebo-controlled RCTs of semaglutide and tirzepatide (40,274 participants) found no clear increase in acute pancreatitis vs placebo (OR 0.99; 95% CI 0.67 to 1.45). Events are rare, so small differences remain hard to exclude.

  • 2026-03-23 (Short bowel syndrome): A review summarized recent evidence on GLP-1 and GLP-2 agonists for short bowel syndrome, with focus on side effects and real-world experience. GLP-1 approaches were framed as promising but less established than GLP-2 drugs.

  • 2026-03-20 (Clinical perspectives): A debate paper summarized what’s known (and unknown) about GLP-1 receptor agonists and fertility, contraception reliability (especially with GI side effects), and pregnancy planning, including suggested washout timelines.

  • 2026-03-19 (Nature Medicine): A large EHR-based target trial emulation in 174,678 patients with type 1 diabetes reported that GLP-1RA initiation was associated with lower risk of major adverse cardiovascular events and end-stage kidney disease, with no observed increase in hospitalization for DKA or severe hypoglycemia.

  • 2026-03 (Real-world self-report map, preprint): A medRxiv analysis of 410k+ Reddit posts summarized commonly self-reported side effects for semaglutide and tirzepatide, and flagged under-discussed symptom clusters. This is not causal evidence, but it can be useful for early signal detection.

Safety reality

GLP-1RAs are prescription medicines with known side effects and contraindications that vary by product and patient context. Outside regulated products, “GLP-1” or “GLP-1RA-like” research chemicals can carry serious identity, dosing, and contamination risks.

This page is informational and does not substitute for medical advice.

References

Xu Y, et al. Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes. Nat Med. (2026). https://pubmed.ncbi.nlm.nih.gov/41857198/ doi:10.1038/s41591-026-04274-0